Get the Stockscreener App
0.595
2.39%
0.0139
After Hours:
.60
0.005
+0.84%
Femasys Inc stock is traded at $0.595, with a volume of 680.88K.
It is up +2.39% in the last 24 hours and down -32.39% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$0.5811
Open:
$0.585
24h Volume:
680.88K
Relative Volume:
0.09
Market Cap:
$35.40M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-0.7169
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
+3.84%
1M Performance:
-32.39%
6M Performance:
-36.11%
1Y Performance:
-46.88%
1-Day Range:
$0.576
$0.6139
1-Week Range:
$0.55
$0.6566
52-Week Range:
$0.3067
$1.80
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.595 | 34.58M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
592.85 | 200.78B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.36 | 56.69B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.81 | 39.62B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
249.19 | 35.81B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
39.77 | 30.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Earnings Beat: Will MARZ stock keep high P E multiples2025 Biggest Moves & Pattern Based Trade Signal System - moha.gov.vn
Femasys gains UK approval for women's health products - MSN
Market Leaders: How strong is Femasys Inc stock balance sheetQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - moha.gov.vn
User | theeveningleader.comFemasys Inc.Common Stock (Nasdaq:FEMY) Stock Quote - FinancialContent
Femasys files for at-the-market offering of up to $9.8 million in common stock - Investing.com India
Femasys Launches At-the-Market Common Stock Offering - TipRanks
Femasys files for at-the-market offering of up to $9.8 million in common stock By Investing.com - Investing.com South Africa
Suwanee company Femasys Inc. gets FDA approval for diagnostic device - The Business Journals
Will Femasys Inc. stock maintain growth story2025 Market Sentiment & Target Return Focused Stock Picks - Улправда
How Femasys Inc. stock reacts to inflationary pressuresTrade Performance Summary & Proven Capital Preservation Tips - Улправда
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more - Contemporary OB/GYN
Swing Trade: Why Femasys Inc. stock is a must watch in 20252025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
What momentum indicators show for Femasys Inc. stockMarket Sentiment Review & Risk Managed Trade Strategies - Bölüm Sonu Canavarı
Why Femasys Inc. stock is rated strong buyJuly 2025 Momentum & Real-Time Volume Spike Alerts - Улправда
Femasys receives FDA clearance for FemVue Controlled diagnostic device By Investing.com - Investing.com Australia
How interest rate cuts could boost Femasys Inc. stockMarket Growth Review & Technical Entry and Exit Tips - Bölüm Sonu Canavarı
How strong is Femasys Inc. stock balance sheet2025 Trading Recap & Consistent Profit Focused Trading Strategies - DonanımHaber
Why Femasys Inc. stock is a must watch in 20252025 Market Sentiment & Growth Oriented Trade Recommendations - Улправда
What analyst consensus says on Femasys Inc. stockJuly 2025 Action & AI Powered Market Trend Analysis - DonanımHaber
Femasys Earnings Notes - Trefis
PharmaCyte Biotech (Nasdaq: PMCB) reports Q2 loss and details QCLS, Femasys deals - Stock Titan
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys gains FDA clearance for FemVue diagnostic device - MSN
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - The Manila Times
Femasys Inc Secures FDA Clearance for FemVue Diagnostic Device - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) secures FDA clearance for next-generation FemVue diagnostic - Stock Titan
Femasys receives FDA clearance for FemVue Controlled diagnostic device - Investing.com
Femasys Inc. Receives FDA Clearance for Innovative FemVue Controlled Device to Enhance Fallopian Tube Evaluation and Workflow Efficiency - Quiver Quantitative
New device could make fallopian tube testing simpler for fertility care - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Secures Major Order for FemBloc Launch - MSN
Femasys Receives FDA Approval for FemBloc Trial - MSN
FDA Approves Final Trial Phase for Femasys’ Permanent Birth Control Product - Medical Product Outsourcing
PharmaCyte’s Successful Stake Earns them Millions - StocksToTrade
PharmaCyte Boosts Financial Position with Femasys Stake Sale - timothysykes.com
Femasys Inc Stock Analysis and ForecastTechnical Breakout Signals & Minimal Capital Trading - earlytimes.in
CapEx per share of Femasys Inc. – NASDAQ:FEMY - TradingView
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen - MarketBeat
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Energy Moves: Why Femasys Inc. stock is a must watch in 2025Weekly Investment Report & Community Verified Trade Alerts - moha.gov.vn
PharmaCyte Biotech sells Femasys stake, boosts cash position to $20 million - Investing.com Nigeria
PharmaCyte Biotech stock soars after successful Femasys stake sale By Investing.com - Investing.com Australia
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):